BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Newcastle Hospitals Clinical Skills Academy - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://skillsacademy.newcastle-hospitals.nhs.uk
X-WR-CALDESC:Events for Newcastle Hospitals Clinical Skills Academy
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20240905T093000
DTEND;TZID=Europe/London:20240905T123000
DTSTAMP:20260405T194208
CREATED:20240614T122313Z
LAST-MODIFIED:20250429T144128Z
UID:10000082-1725528600-1725539400@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Targeted Treatments and Immunotherapy for Solid Tumours: Demystifying the Science - September 2024
DESCRIPTION:Please note this course has been rearranged to start in February 2025.  Please follow the link for the course booking page: February 2025 course booking page\nThis course gives cancer nurses and trial staff the knowledge and confidence to discuss a wide range of targeted cancer treatments and immunotherapies with patients and colleagues. \nOverview\nThis course focuses on cancer biology and the science behind licensed treatments for solid tumours\, including monoclonal antibodies\, small molecule kinase inhibitors\, and immunotherapies. \nOver the course of two mornings\, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will guide you through the scientific concepts that underpin many of the most used targeted cancer treatments and immunotherapies for solid tumours. \nTreatments discussed include those that target cell communication pathways (e.g. EGFR and HER2-targeted treatments) and immune checkpoint inhibitors. Elaine also describes various molecular features of cancer that underpin many other new treatments. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also interest other healthcare professionals wanting to improve their understanding of targeted treatments and immunotherapy. \nAs ever\, Elaine will use colourful illustrations and jargon-free explanations to help learners gain a broad understanding of the concepts covered. \nCourse delivery\nThe course comprises two mornings delivered online via Microsoft Teams as follows: \nSession One – Targeted cancer treatments\nOver three presentations\, Dr Vickers guides us through the scientific concepts underpinning many of the most used targeted cancer treatments. Beginning with the bigger picture – what we can and can’t target – she then describes the mechanisms of action of the two main types of treatment: monoclonal antibodies that target cell surface proteins and small molecules that block kinases. \nMany of these treatments target cell communication pathways. Elaine will explain the function of these pathways in healthy cells and their defects in cancer cells. She’ll also describe why blocking these pathways sometimes works and sometimes doesn’t. \nLastly\, Elaine turns her attention to other targets and discusses when a targeted therapy or immunotherapy approach is more likely to work. \nTargeted cancer treatments – the current landscape \n\nDescribing the ‘Enabling Characteristics’ that allow cancer to develop and the ‘Hallmarks of Cancer Cells’ that drive cancer’s behaviour\nWhich can we target\, and how can we do it?\nThe pros and cons of small molecule inhibitors and monoclonal antibodies\n\nTreatments that target cell communication \n\nTargeting growth factor receptors such as EGFR\, HER2\, and MET\nInhibitors of growth factor receptor fusion proteins: ALK\, ROS1\, RET\, TRKA/B/C\nB-Raf & MEK inhibitors for BRAF-mutated cancers\nThe pros and cons of PI3K & mTOR inhibitors\nProgress in targeting Ras proteins\n\nOther targets and treatments \n\nThe mechanism of action and limitations of angiogenesis inhibitors\nPARP inhibitors for cancers with defects in homologous recombination\nCDK inhibitors for hormone-sensitive breast cancer\nWhen is targeted therapy or immunotherapy the best strategy?\n\nSession 2: Cancer immunotherapy \nThe focus of this morning is on cancer’s relationship with the immune system and how this knowledge is being used to improve the outlook of people with various solid tumours. \nElaine describes how checkpoint inhibitors boost cancer-fighting T cells. She also highlights some of the lessons learned through the hundreds of clinical trials with checkpoint inhibitors that have taken place over the past decade. \nLastly\, Elaine explains how other forms of immunotherapy aim to create an anti-cancer immune response. \nAn introduction to immunotherapy \n\nA brief introduction to the immune system\nHow cancer’s relationship with the immune system changes over time\nHow the immune system can recognise and react to the presence of cancer in the body – the Cancer Immunity Cycle\nMechanisms of immune evasion by cancer cells\nAn overview of immunotherapy approaches and the importance of T cells\nReasons why immunotherapy sometimes does work and sometimes doesn’t\n\nImmunotherapy with checkpoint inhibitors \n\nIntroduction to checkpoint proteins on T cells\nDescribing the mechanism of action of checkpoint inhibitors\nSpot the difference: CTLA-4 and PD-1/P-L1 targeted checkpoint inhibitors\nSome of the many lessons learned from clinical trials with checkpoint inhibitors\n\nBiomarkers and combinations; other forms of immunotherapy \n\nDescribing the use of biomarkers to predict which patients will benefit from checkpoint inhibitors: what have we got and what’s coming?\nTreatment combinations to improve response rates\nNovel checkpoint inhibitors\nA broader look at immunotherapy strategies to create cancer-fighting T cells and the progress made in using them as treatments for solid tumours\nLooking to the future of immunotherapy for solid tumours\n\nDelegates will be given access to recordings of all sessions for three months after completion of the course. If you are unable to attend a session the recording will ensure you can review any content you have missed. \nCourse Lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading \nmedical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nThe second edition of her book\, A Beginner’s Guide to Targeted Cancer Treatments – commended by the British Medical Association book awards is due out by the end of 2024. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/targeted-treatments-and-immunotherapy-for-solid-tumours-demystifying-the-science-september-2024/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/Gene-therapy-for-cancer-concept-illustration-slim-for-course.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
END:VCALENDAR